CRISPR cancer therapy trial halted: what happened with CTX110?
Disease control
Terminated
This study tested a one-time treatment using CRISPR-edited immune cells from a donor (CTX110) in 93 adults with B-cell cancers like lymphoma or leukemia that had come back or stopped responding to other treatments. The goal was to see if these cells were safe and could shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 14, 2026 12:06 UTC